AR121810A2 - PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS - Google Patents
PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODSInfo
- Publication number
- AR121810A2 AR121810A2 ARP210100947A ARP210100947A AR121810A2 AR 121810 A2 AR121810 A2 AR 121810A2 AR P210100947 A ARP210100947 A AR P210100947A AR P210100947 A ARP210100947 A AR P210100947A AR 121810 A2 AR121810 A2 AR 121810A2
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- lymphocyte
- peptide
- antibody
- kit
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 108091008874 T cell receptors Proteins 0.000 title abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con péptidos, proteínas, ácidos nucleicos y células para su uso en métodos inmunoterapéuticos. En particular, la presente invención se relaciona con inmunoterapia para el cáncer. La presente invención se relaciona además con epitopes de péptidos de células T asociados con tumores, solos o en combinación con otros péptidos asociados con tumores que pueden, por ejemplo, servir como ingredientes farmacéuticos activos de composiciones para vacunas que estimulan la respuesta inmune antitumoral o para estimular células T ex vivo y transferirlas a pacientes. Los péptidos unidos a moléculas del complejo de histocompatibilidad principal (MHC) o los péptidos como tales también pueden ser el blando de anticuerpos, receptores de células T solubles y otras moléculas de unión.The present invention relates to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, the present invention relates to cancer immunotherapy. The present invention further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can, for example, serve as active pharmaceutical ingredients of compositions for vaccines that stimulate antitumor immune response or for stimulate T cells ex vivo and transfer them to patients. Peptides bound to major histocompatibility complex (MHC) molecules or peptides as such may also be the target of antibodies, soluble T cell receptors and other binding molecules.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139189P | 2015-03-27 | 2015-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121810A2 true AR121810A2 (en) | 2022-07-13 |
Family
ID=59256464
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100818A AR104113A1 (en) | 2015-03-27 | 2016-03-28 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
| ARP180102260A AR112781A2 (en) | 2015-03-27 | 2018-08-08 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
| ARP210100947A AR121810A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100945A AR121809A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100948A AR121811A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100949A AR121812A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210102531A AR123493A2 (en) | 2015-03-27 | 2021-09-13 | PEPTIDE, NUCLEIC ACID, EXPRESSION VECTOR, RECOMBINANT HOST CELL, ANTIBODY, KIT, PHARMACEUTICAL COMPOSITION AND RELATED METHODS |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100818A AR104113A1 (en) | 2015-03-27 | 2016-03-28 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
| ARP180102260A AR112781A2 (en) | 2015-03-27 | 2018-08-08 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100945A AR121809A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100948A AR121811A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100949A AR121812A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210102531A AR123493A2 (en) | 2015-03-27 | 2021-09-13 | PEPTIDE, NUCLEIC ACID, EXPRESSION VECTOR, RECOMBINANT HOST CELL, ANTIBODY, KIT, PHARMACEUTICAL COMPOSITION AND RELATED METHODS |
Country Status (1)
| Country | Link |
|---|---|
| AR (7) | AR104113A1 (en) |
-
2016
- 2016-03-28 AR ARP160100818A patent/AR104113A1/en not_active Application Discontinuation
-
2018
- 2018-08-08 AR ARP180102260A patent/AR112781A2/en not_active Application Discontinuation
-
2021
- 2021-04-09 AR ARP210100947A patent/AR121810A2/en not_active Application Discontinuation
- 2021-04-09 AR ARP210100945A patent/AR121809A2/en not_active Application Discontinuation
- 2021-04-09 AR ARP210100948A patent/AR121811A2/en not_active Application Discontinuation
- 2021-04-09 AR ARP210100949A patent/AR121812A2/en not_active Application Discontinuation
- 2021-09-13 AR ARP210102531A patent/AR123493A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR104113A1 (en) | 2017-06-28 |
| AR121812A2 (en) | 2022-07-13 |
| AR123493A2 (en) | 2022-12-07 |
| AR112781A2 (en) | 2019-12-11 |
| AR121809A2 (en) | 2022-07-13 |
| AR121811A2 (en) | 2022-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127117A2 (en) | NOVEL PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | |
| CL2023001346A1 (en) | Use of peptides in immunotherapy against small cell lung cancer and others. | |
| CL2021002525A1 (en) | Immunotherapeutic peptides for use in cancer immunotherapy (divisional of application no. 201801531) | |
| CL2020000987A1 (en) | New peptide from seq id no: 89 for use in immunotherapy against lung cancer, including small cell lung cancer and other cancers (divisional application no. 201701819) | |
| CL2020001985A1 (en) | Peptides and peptide combinations for use in immunotherapy against chronic lymphocytic leukemia (LLC) and other cancers. (divisional request 201801532) | |
| CL2018000780A1 (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other types of cancer | |
| MX2023014146A (en) | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers. | |
| AR121019A2 (en) | PEPTIDE, ENCODING NUCLEIC ACID, ANTIBODY, T-LYMPHOCYTE, T-LYMPHOCYTE RECEPTOR, APTAMER, RECOMBINANT HOST CELL, PHARMACEUTICAL COMPOSITION AND EQUIPMENT | |
| CR20180001A (en) | NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER TYPES OF CANCER. | |
| CO2019008008A2 (en) | New peptides and new peptide combinations for use in immunotherapy against ovarian and other cancers | |
| MX2017011857A (en) | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers. | |
| CR20200493A (en) | NEW PEPTIDES, PEPTIDE COMBINATIONS AND SUPPORTS FOR USE IN THE IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS TYPES OF CANCER (Divisional 2018-174) | |
| MX2020012777A (en) | NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS TO CREATE SUPPORTS FOR USE AGAINST PANCREATIC CANCER AND OTHER TYPES OF CANCER. | |
| CR20210067A (en) | NEW PEPTIDES AND SUPPORT STRUCTURES FOR USE IN IMMUNOTHERAPY AGAINST EPIDERMOID CARCINOMA OF THE HEAD AND NECK AND OTHER CANCER (Divisional 2019-0094) | |
| CL2017002407A1 (en) | Peptides and combination of novel peptides for use in immunotherapy against various tumors | |
| MX2022002263A (en) | NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES AND SUPPORTS FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA AND OTHER TYPES OF CANCER. | |
| MX2022005570A (en) | NEW PEPTIDES AND NEW COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREAS CANCER AND OTHER TYPES OF CANCER. | |
| AR121809A2 (en) | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS | |
| CR20170522A (en) | PEPTIDES AND COMBINATION OF NOVELED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |